论文部分内容阅读
目的探讨趋化因子受体CXCR4和CCR7在甲状腺癌中的表达及其临床病理意义。方法选取2006～2009年期间在我院行手术治疗的甲状腺癌患者55例和2009年在我院行手术治疗的甲状腺腺瘤患者30例,采用免疫组织化学染色SP法检测甲状腺癌及甲状腺腺瘤组织中的CXCR4和CCR7的表达。结果 CXCR4和CCR7在甲状腺癌中的表达阳性率均明显高于甲状腺腺瘤(P<0.01)。CXCR4和CCR7在临床分期为Ⅲ+Ⅳ期的甲状腺癌患者中的表达阳性率均明显高于临床分期为Ⅰ+Ⅱ期者(P<0.05);CCR7在有淋巴结转移的甲状腺癌中的表达阳性率明显高于无淋巴结转移者(P<0.05),而CXCR4的表达阳性率与甲状腺癌患者有无淋巴结转移无关(P>0.05);CXCR4和CCR7在甲状腺癌组织中的表达阳性率与甲状腺癌患者的年龄和性别均无关(P>0.05)。在甲状腺癌中,CXCR4阳性表达和CCR7阳性表达呈正相关(rs=0.491,P=0.000)。结论 CXCR4和CCR7协同参与了甲状腺癌的进展,可作为判断甲状腺癌预后的指标;CCR7高表达提示甲状腺癌容易发生淋巴结转移。
Objective To investigate the expression of chemokine receptors CXCR4 and CCR7 in thyroid carcinoma and its clinicopathological significance. Methods Fifty-five thyroid cancer patients surgically treated in our hospital from 2006 to 2009 and 30 thyroid adenoma patients surgically treated in our hospital from 2009 to 2009. Thyroid cancer and thyroid adenoma were detected by immunohistochemical SP method CXCR4 and CCR7 expression in tissues. Results The positive rates of CXCR4 and CCR7 in thyroid cancer were significantly higher than those in thyroid adenoma (P <0.01). The positive rates of CXCR4 and CCR7 in thyroid cancer patients with clinical stage Ⅲ + Ⅳ were significantly higher than those with clinical stage Ⅰ + Ⅱ (P <0.05). The positive expression rate of CCR7 in thyroid cancer with lymph node metastasis (P <0.05), while the positive expression rate of CXCR4 was not correlated with lymph node metastasis in patients with thyroid cancer (P> 0.05). The positive rate of CXCR4 and CCR7 in thyroid cancer was significantly higher than that in thyroid cancer There was no correlation between age and sex of the patients (P> 0.05). In thyroid cancer, CXCR4 positive expression was positively correlated with CCR7 positive expression (rs = 0.491, P = 0.000). Conclusion CXCR4 and CCR7 are synergistic involved in the progression of thyroid cancer, which may be used as an index to judge the prognosis of thyroid cancer. High expression of CCR7 suggests that lymph node metastasis is likely to occur in thyroid cancer.